Quinoclamine

Research use only, not for human use.

Quinoclamine is a naphthoquinone derivative and is an NF-κB inhibitor.

Quinoclamine is a naphthoquinone derivative and is an NF-κB inhibitor.

Quinoclamine causes differentiation of U-937 cells into macrophage-like cells.Quinoclamine inhibits NF-κB activities in HepG2 cells, with an IC50 of 1.7 μM.Quinoclamine (1-4 μM; 30 minutes ) suppresses endogenous NF-κB activity in HepG2 cells through the inhibition of IκB-α phosphorylation and p65 translocation.Quinoclamine inhibits induced NF-κB activities in lung and breast cancer cell lines.Quinoclamine affects the expression levels of genes involved in cell cycle or apoptosis.Quinoclamine down-regulates the expressions of UDP glucuronosyltransferase genes involved in phase II drug metabolism. Cell Viability Assay Cell Line:HepG2 cells Concentration:1 μM, 2 μM, 4 μM, 8 μM, 16 μM, 32 μM, 64 μM Incubation Time:24 hours Result:Inhibited NF-κB activities in HepG2 cells. Western Blot Analysis Cell Line:HepG2 cells Concentration:0 μM, 1 μM, 2 μM, 4 μM Incubation Time:30 minutes Result:Inhibited IκB-α phosphorylation and p65 translocation in HepG2 cells.

——

——

Apoptosis

NF-κB

NF-κB

——

——

2797-51-5

207.61

C10H6ClNO2

>98% (HPLC)

DMSO:250 mg/mL (1204.18 mM; Need ultrasonic)

C1=CC=C2C(=C1)C(=O)C(=C(C2=O)Cl)N

——

(-20℃)

With Ice Pack

≥ 2 years